Are oral isotretinoin rinses effective for the prevention of oral cavity squamous cell carcinoma (OCSCC), squamous cell carcinoma (SCC) in situ, and dysplasia?
Oral isotretinoin as chemoprophylaxis for patients treated for oral cavity squamous cell carcinoma, in situ disease, or dysplasia may be beneficial in decreasing recurrence rate.
Explore this issue:July 2017
Background: Over the past three decades, there have been only minor advancements within the field of chemoprevention and chemoprophylaxis. The idea of condemned mucosa and field cancerization ignited an early interest in chemoprevention strategies but, ultimately, an efficacious, well-tolerated agent has yet to be found. The primary aim of this study was to demonstrate the experience of a single group practice with reconstituted oral isotretinoin rinses for the prevention of oral cavity squamous cell carcinoma (OCSCC), squamous cell carcinoma (SCC) in situ, and dysplasia. As irritation is the only side effect, and most insurance companies are willing to cover this drug, this low-risk therapy could prove to be a useful adjunct in the treatment of this patient population.
Study design: Retrospective cohort study.